Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 4Vincristine 3Doxorubicin 3romidepsin 2fludarabine 2Rituximab 2Oxaliplatin 2Lenalidomide 2Etoposide 2Azacitidine 2Alemtuzumab 2siplizumab 1obatoclax 1liposomal doxorubicin 1gossypol acetic acid 1fludarabine phosphate 1cediranib 1cc-486 1Valproic Acid 1Taxes 1Sunitinib 1Spinal Puncture 1Sorafenib 1Receptors, Chimeric Antigen 1Razoxane 1Prednisone 1Prednisolone 1Polymerase Chain Reaction 1Paclitaxel 1Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, T-Cell, Peripheral × Abatacept × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡